Anbio Biotechnology（N3B）株式概要アンバイオ・バイオテクノロジー社は、欧州連合、アジア太平洋地域、北米、南米、アフリカ、そして国際的に体外診断用医薬品（IVD）を提供している。 詳細N3B ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績4/6財務の健全性6/6配当金0/6報酬過去1年間で収益は169.9%増加しました リスク分析高いレベルの非現金収入 過去5年間で収益は年間3.4%減少しました。 German市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るN3B Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW463,021 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA463,021 investors already sharing narrativesYour Fair Value€Current Price€6.4033.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture024m2016201920222025202620282031Revenue US$8.6mEarnings US$6.4mAdvancedSet Fair ValueView all narrativesAnbio Biotechnology 競合他社NovogeniaSymbol: MUN:7V0Market cap: €69.6m2investSymbol: XTRA:2INVMarket cap: €62.9mYantai Zhenghai BiotechnologySymbol: SZSE:300653Market cap: CN¥2.7bMedicalsystem BiotechnologySymbol: SZSE:300439Market cap: CN¥3.7b価格と性能株価の高値、安値、推移の概要Anbio Biotechnology過去の株価現在の株価US$6.4052週高値US$42.6052週安値US$6.40ベータ01ヶ月の変化-20.99%3ヶ月変化-74.80%1年変化-84.98%3年間の変化n/a5年間の変化n/aIPOからの変化8.47%最新ニュースValuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.15, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past year.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €9.80, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 72% over the past year.Valuation Update With 7 Day Price Move • Jul 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.80, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year.New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio).Board Change • May 21High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.15, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past year.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €9.80, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 72% over the past year.Valuation Update With 7 Day Price Move • Jul 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.80, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year.New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio).Board Change • May 21High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.お知らせ • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.株主還元N3BDE BiotechsDE 市場7D-22.4%-1.3%-0.8%1Y-85.0%4.4%2.4%株主還元を見る業界別リターン: N3B過去 1 年間で4.4 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: N3Bは、過去 1 年間で2.4 % のリターンを上げたGerman市場を下回りました。価格変動Is N3B's price volatile compared to industry and market?N3B volatilityN3B Average Weekly Movement16.8%Biotechs Industry Average Movement5.9%Market Average Movement5.2%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.6%安定した株価: N3Bの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: N3Bの weekly volatility ( 17% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト202127Michael Lauwww.anbiobiotechnology.comアンビオバイオテクノロジー社は、体外診断用医薬品（IVD）製品を欧州連合、アジア太平洋地域、北米、南米、アフリカ、および国際的に提供している。SARS-CoV-2抗原迅速検査、SARS-CoV-2/インフルエンザA/B抗原迅速検査、ラテラルフロー免疫測定、蛍光免疫測定、ループ媒介等温増幅、化学発光免疫測定、逆転写ポリメラーゼ連鎖反応製品を提供している。市販薬、ポイントオブケア検査、ラボラトリー市場にサービスを提供している。同社は2021年に設立され、ドイツのフランクフルト・アム・マインに本社を置いている。もっと見るAnbio Biotechnology 基礎のまとめAnbio Biotechnology の収益と売上を時価総額と比較するとどうか。N3B 基礎統計学時価総額€291.31m収益（TTM）€5.48m売上高(TTM)€7.41m50.2xPER（株価収益率37.2xP/SレシオN3B は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計N3B 損益計算書（TTM）収益US$8.65m売上原価US$1.10m売上総利益US$7.54mその他の費用US$1.14m収益US$6.40m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.15グロス・マージン87.24%純利益率74.06%有利子負債／自己資本比率0%N3B の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/20 16:56終値2026/08/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Anbio Biotechnology 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.15, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past year.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €9.80, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 72% over the past year.
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.80, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year.
New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio).
Board Change • May 21High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.
お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €7.15, the stock trades at a trailing P/E ratio of 57.2x. Average trailing P/E is 23x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past year.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €9.80, the stock trades at a trailing P/E ratio of 71.1x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 72% over the past year.
Valuation Update With 7 Day Price Move • Jul 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €9.80, the stock trades at a trailing P/E ratio of 78.8x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 74% over the past year.
New Risk • Jun 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 3.4% per year over the past 5 years. High level of non-cash earnings (111% accrual ratio).
Board Change • May 21High number of new directorsIndependent Director Michael Zhang was the last director to join the board, commencing their role in 2026.
お知らせ • Jan 27Anbio Biotechnology Announces Board and Committee Changes, Effective January 21, 2026Effective January 21, 2026, as approved by the Board of Directors, the Nominating Committee and the Compensation Committee of Anbio Biotechnology, Michael Zhang was appointed as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Michael Zhang would replace Kenneth Li as a director, the Chair of Audit Committee, a member of Nominating Committee and a member of Compensation Committee. Kenneth Li’s departure was not a result of any disagreement with the Company’s operations, policies or procedures. Michael Zhang has over 30 years’ experience in finance. He has worked as a managing partner, overseeing all corporate finance and investment-related matters at Healthcare Alpha Management since 2014. He obtained his bachelor’s degree in business from Indiana University Bloomington in 1996 and master’s degree in business administration from Yale University in 2004.
お知らせ • Oct 10Anbio Biotechnology Showcases Diagnostic Portfolio At WSAVA 2025Anbio Biotechnology participated in the 50th World Small Animal Veterinary Association Congress (WSAVA 2025), an international gathering that brought together veterinarians, researchers, and industry representatives from more than 100 countries. The event provided a platform for Anbio to present its veterinary diagnostic portfolio and exchange views with partners across global markets. At WSAVA 2025, Anbio displayed five product lines: Fluorescence Immunoassay (FIA); Dry Chemistry; Molecular Diagnostics; Colloidal Gold Rapid Tests; Dry Chemiluminescence Immunoassay (CLIA). The portfolio generated interest among veterinarians, distributors, and industry participants. The dry chemistry and fluorescence immunoassay systems were noted for their precision and usability, while discussions with distributors reflected demand for accessible and accurate testing technologies in veterinary healthcare. A key feature was Anbio's molecular diagnostics platform, capable of producing multi-target real-time PCR results within 15 minutes. This function was highlighted as a practical option for the rapid detection of respiratory and infectious diseases in animals, where timely results are critical to clinical management. Delegates pointed to the relevance of such technologies in strengthening outbreak response and supporting routine diagnostic workflows. The exhibition also provided opportunities for Anbio to engage with existing and potential partners, discuss distribution strategies, and consider future product rollouts. These exchanges underlined the increasing role of point-of-care diagnostics in veterinary practice and emphasized the importance of international collaboration in expanding access to diagnostic tools. Looking ahead, Anbio will continue its global outreach. The company is scheduled to participate in the Wild West Vet Show 2025, taking place from October 15-18, 2025, in Reno, Nevada, USA. The exhibition will provide another opportunity to present its veterinary diagnostic portfolio. Anbio's participation in WSAVA 2025 reflects its continuing efforts in both human and veterinary diagnostics. By advancing practical and reliable testing solutions, the company contributes to improving healthcare outcomes in diverse settings worldwide.
